Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC) No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results